AZD1152 in Patients With Advanced Solid Malignancies-Study 3
Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152
when given as a continuous 7-day infusion every week and every 2 weeks in patients with
advanced solid malignancies.